The Gulf Familial Hypercholesterolemia Registry (Gulf FH): Design, Rationale and Preliminary Results.


Journal

Current vascular pharmacology
ISSN: 1875-6212
Titre abrégé: Curr Vasc Pharmacol
Pays: United Arab Emirates
ID NLM: 101157208

Informations de publication

Date de publication:
2020
Historique:
received: 11 08 2018
revised: 01 10 2018
accepted: 01 10 2018
pubmed: 6 10 2018
medline: 29 9 2020
entrez: 6 10 2018
Statut: ppublish

Résumé

To determine the prevalence, genetic characteristics, current management and outcomes of familial hypercholesterolaemia (FH) in the Gulf region. Adult (18-70 years) FH patients were recruited from 9 hospitals and centres across 5 Arabian Gulf countries. The study was divided into 4 phases and included patients from 3 different categories. In phase 1, suspected FH patients (category 1) were collected according to the lipid profile and clinical data obtained through hospital record systems. In phase 2, patients from category 2 (patients with a previous clinical diagnosis of FH) and category 1 were stratified into definitive, probable and possible FH according to the Dutch Lipid Clinic Network criteria. In phase 3, 500 patients with definitive and probable FH from categories 1 and 2 will undergo genetic testing for 4 common FH genes. In phase 4, these 500 patients with another 100 patients from category 3 (patients with previous genetic diagnosis of FH) will be followed for 1 year to evaluate clinical management and cardiovascular outcomes. The Gulf FH cohort was screened from a total of 34,366 patients attending out-patient clinics. The final Gulf FH cohort consisted of 3,317 patients (mean age: 47±12 years, 54% females). The number of patients with definitive FH is 203. In this initial phase of the study, the prevalence of (probable and definite) FH is 1/232. The prevalence of FH in the adult population of the Arabian Gulf region is high. The Gulf FH registry, a first-of-a-kind multi-national study in the Middle East region, will help in improving underdiagnosis and undertreatment of FH in the region.

Identifiants

pubmed: 30289081
pii: CVP-EPUB-93470
doi: 10.2174/1570161116666181005125459
pmc: PMC7040511
doi:

Substances chimiques

Biomarkers 0
Lipids 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

57-64

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Références

J Atheroscler Thromb. 2017 Oct 1;24(10):1075-1084
pubmed: 28344196
Lancet. 2015 Jan 24;385(9965):331-40
pubmed: 25282519
Eur Heart J. 2014 Aug 21;35(32):2146-57
pubmed: 25053660
Expert Rev Cardiovasc Ther. 2008 Apr;6(4):567-81
pubmed: 18402545
Heart. 2011 Jul;97(14):1175-81
pubmed: 21685482
Vasc Health Risk Manag. 2010 Nov 10;6:1023-37
pubmed: 21127699
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Open Cardiovasc Med J. 2014 Sep 25;8:88-93
pubmed: 25328551
J Med Genet. 1995 Aug;32(8):623-6
pubmed: 7473654
Clin Genet. 1976 Feb;9(2):203-33
pubmed: 174852
J Clin Lipidol. 2015 Mar-Apr;9(2):187-94
pubmed: 25911074
Curr Vasc Pharmacol. 2015;13(6):759-70
pubmed: 26311574
Acta Cardiol. 2009 Aug;64(4):439-46
pubmed: 19725435
J Clin Lipidol. 2017 Jan - Feb;11(1):260-271
pubmed: 28391894
Atherosclerosis. 2015 Jul;241(1):169-75
pubmed: 25997074
Open Cardiovasc Med J. 2017 Jul 26;11:66-75
pubmed: 28868092
Semin Vasc Med. 2004 Feb;4(1):97-104
pubmed: 15199439
Healthcare (Basel). 2015 Oct 26;3(4):1018-30
pubmed: 27417810
Eur Heart J. 2013 Dec;34(45):3478-90a
pubmed: 23956253
J Clin Lipidol. 2018 May - Jun;12(3):685-692.e2
pubmed: 29574074
Atherosclerosis. 2016 Sep;252:182-187
pubmed: 27522462
Angiology. 2014 Nov;65(10):911-8
pubmed: 24249837
Am J Epidemiol. 2004 Sep 1;160(5):407-20
pubmed: 15321837
Atherosclerosis. 2012 Feb;220(2):429-36
pubmed: 22129472
Eur Heart J. 2015 Nov 14;36(43):2996-3003
pubmed: 26330422
J Am Coll Cardiol. 2018 Aug 7;72(6):662-680
pubmed: 30071997
J Clin Invest. 2003 Jun;111(12):1795-803
pubmed: 12813012
Angiology. 2014 Nov;65(10):919-26
pubmed: 24301426
Ann Saudi Med. 2012 Jan-Feb;32(1):9-18
pubmed: 22156634
Atherosclerosis. 2004 Mar;173(1):55-68
pubmed: 15177124
PLoS One. 2017 Aug 17;12(8):e0183494
pubmed: 28817709
J Clin Endocrinol Metab. 2012 Nov;97(11):3956-64
pubmed: 22893714
Angiology. 2013 May;64(4):287-92
pubmed: 23162007
Gene. 2015 Jul 1;565(1):76-84
pubmed: 25839937
Int J Cardiol. 2016 Dec 15;225:268-283
pubmed: 27741487
Eur Heart J. 2015 Sep 21;36(36):2438-45
pubmed: 26142466
Atherosclerosis. 2015 May;240(1):190-6
pubmed: 25797312
Atherosclerosis. 2012 Aug;223(2):262-8
pubmed: 22398274
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Clin Chem. 2018 Feb;64(2):355-362
pubmed: 29038147

Auteurs

Khalid Al-Rasadi (K)

Department of Clinical Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman.

Khalid F Alhabib (KF)

Department of Cardiac Sciences, King Fahad Cardiac Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Faisal Al-Allaf (F)

Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makka, Saudi Arabia.

Khalid Al-Waili (K)

Department of Clinical Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman.

Ibrahim Al-Zakwani (I)

Department of Pharmacology & Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
Gulf Health Research, Muscat, Oman.

Ahmad AlSarraf (A)

Department of Medical Biochemistry, Ministry of Health, Kuwait City, Safat, Kuwait.

Wael Almahmeed (W)

Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.

Nasreen AlSayed (N)

Gulf Diabetes Specialist Center, Manama, Bahrain.

Mohammad Alghamdi (M)

National Guard Hospital, Riyadh, Saudi Arabia.

Mohammed A Batais (MA)

Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Turky H Almigbal (TH)

Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Fahad Alnouri (F)

Cardiovascular Prevention Unit, Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia.

Abdulhalim Kinsara (A)

King Saud bin Abdulaziz University for Health Sciences, College of Medicine, King Abdul Aziz Medical City, Jeddah, Saudi Arabia.

Ashraf Hammouda (A)

Saud Al Babtain Cardiac Center, Dammam, Saudi Arabia.

Zuhier Awan (Z)

King Abdulaziz University, Jeddah, Saudi Arabia.

Heba Kary (H)

King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.

Omer A Elamin (OA)

King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.

Fahad Zadjali (F)

Department of Biochemistry, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.

Mohammed Al-Jarallah (M)

Department of Medicine, Sabah Al-Ahmed Cardiac Center, Kuwait.

Abdullah Shehab (A)

Department of Internal Medicine, College of Medicine and Health Sciences, UAE; University, Al Ain, United Arab Emirates.

Hani Sabbour (H)

Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.

Haitham Amin (H)

Bahrain Defense Force Hospital, Riffa, Bahrain.

Hani Altaradi (H)

Department of Cardiac Sciences, King Fahad Cardiac Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH